Results 161 to 170 of about 664,100 (294)

Targeting of the CD161 Inhibitory Receptor Enhances Bone‐Marrow‐Resident Memory CD8+ T‐Cell‐Mediated Immunity against Multiple Myeloma

open access: yesAdvanced Science, EarlyView.
CD161 is identified as a novel inhibitory receptor on bone marrow (BM)‐resident CD8⁺ T cells in multiple myeloma (MM). Through interaction with its ligand CLEC2D, CD161 impairs T‐cell function and promotes immune suppression. Blockade of CD161 restores tissue residency and cytotoxicity of CD8⁺ T cells and enhances chimeric antigen receptor T‐cell (CAR ...
Liwen Wang   +16 more
wiley   +1 more source

Diagnostic significance of the histologic changes in the liver and spleen in leukemia and malignant lymphoma [PDF]

open access: bronze, 1965
Nikola D. Kostich, Henry Rappaport
openalex   +1 more source

Intracellular Mechanical Stress‐Mediated Autophagy Cell Death via Nanospikes for Cancer Treatment

open access: yesAdvanced Science, EarlyView.
Nanospikes with tunable morphology at the nanoscale induce lysosomal membrane damage by generating localized mechanical stress, activating Galectin‐3 (Gal3)‐Trim16‐mediated autophagic cell death. Finite element analysis and laser‐triggered spike ablation enable precise control of intracellular force signaling and cytotoxicity, offering a ...
Yingze Li   +11 more
wiley   +1 more source

Dihydrofolate Reductase from the L1210 R Murine Lymphoma

open access: hybrid, 1967
Brian L. Hillcoat   +2 more
openalex   +1 more source

Progress in treatment for the leukemias and lymphomas [PDF]

open access: bronze, 1965
Emil Frei
openalex   +1 more source

Lymphoma Erysipeloides

open access: yesIDCases, 2020
Erkilic, Gamze   +5 more
openaire   +4 more sources

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

open access: yesAdvanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy